Research
The Yale Center for Asthma and Airways Diseases (YCAAD) is a highly regarded academic clinical center recognized for its excellence in education, research, and patient care. The center consists of three programs: the Asthma Program, the Bronchiectasis and Nontuberculous Mycobacteria (NTM) Infections Program, and the Chronic Obstructive Pulmonary Disease (COPD) Program.
Established in 2000, YCAAD provides opportunities for patients with complicated airway diseases to participate in innovative research through industry-sponsored clinical trials and NIH-funded translational research. In addition to advancing cutting-edge research to improve patients’ lives, YCAAD is committed to training the next generation of leaders in the field. The center provides education opportunities for students, residents, fellows, and health care providers around the region on the cutting-edge management of airway diseases.
Publications
Copy Link
2025
- Peer-Reviewed Original ResearchSex-biased gene expressionClinical featuresGene expressionType 2 inflammationClinical features of asthmaFeatures of asthmaAssociated with differential gene expressionExpression levelsImmune dysfunctionLocal validation cohortAdult patientsGene expression databaseValidation cohortImmune cellsClinical correlatesDifferential gene expressionGene expression differencesLymphocyte proliferationAllergic responsesAdult subjectsGene expression effectsGenetic polymorphismsImmune allergic responsesBlood samplesFemale genomes
Down Syndrome Alters Type III IFN and Proinflammatory Airway Epithelial Responses to Respiratory Syncytial Virus Infection.
Chorvinsky E, Bhattacharya S, Bera B, Welham A, Ismat K, Lawlor C, Preciado D, Gomez J, Morizono H, Pillai D, Gutierrez M, Jaiswal J, Nino G. Down Syndrome Alters Type III IFN and Proinflammatory Airway Epithelial Responses to Respiratory Syncytial Virus Infection. American Journal Of Respiratory Cell And Molecular Biology 2025, 73: 951-964. PMID: 40587878, PMCID: PMC12699336, DOI: 10.1165/rcmb.2025-0068oc.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAirway epithelial cellsRSV infectionType III IFNsViral infectionDown syndromeNasal airway epithelial cellsResponse to RSV infectionSeverity of RSV infectionRSV-induced responsesSevere viral bronchiolitisAirway immune responsesRespiratory syncytial virusPro-inflammatory statePro-inflammatory cytokinesPro-inflammatory responseEnhanced viral infectionType III IFN responseViral bronchiolitisSyncytial virusImmunological basisPediatric donorsPrimary sitePro-inflammatoryImmune responseEpithelial cellsWork Practices and Respirable Crystalline Silica Exposures in Stone Countertop Fabrication Shops
McGowan C, Cantley L, Klein R, Redlich C. Work Practices and Respirable Crystalline Silica Exposures in Stone Countertop Fabrication Shops. American Journal Of Industrial Medicine 2025, 68: 973-987. PMID: 40946211, DOI: 10.1002/ajim.70020.Peer-Reviewed Original ResearchPediatric Airway Biology and Transcriptomic Assessment of Therapies
Nino G, Gomez J, Gutierrez M. Pediatric Airway Biology and Transcriptomic Assessment of Therapies. JAMA Pediatrics 2025, 179: 947-949. PMID: 40658411, DOI: 10.1001/jamapediatrics.2025.2070.Peer-Reviewed Original ResearchAltmetricMepolizumab in patients with severe asthma and blood eosinophil counts between 150 and 300 cells per µL: benefits at two years
Canonica G, Bagnasco D, Lee J, Chupp G, Schleich F, Oppenheimer J, Zhang L, Alfonso-Cristancho R, Howarth P. Mepolizumab in patients with severe asthma and blood eosinophil counts between 150 and 300 cells per µL: benefits at two years. ERJ Open Research 2025, 11: 01390-2024. PMID: 41220814, PMCID: PMC12598589, DOI: 10.1183/23120541.01390-2024.Peer-Reviewed Original ResearchAltmetricConceptsClinically significant exacerbationsBlood eosinophil countMaintenance oral corticosteroidsSevere asthmaRate of clinically significant exacerbationsMedian average daily doseFEV 1Effect of mepolizumabInitiation of mepolizumabProportion of patientsObservational cohort studyReal-world effectivenessClinical trial evidenceForced expiratory volumePoor disease controlMepolizumab treatmentAverage daily doseOral corticosteroidsSingle-armACQ-5Daily doseSignificant exacerbationsEosinophil countMepolizumabCohort studyImpact of Demographics on Mepolizumab Effectiveness in Severe Asthma: One-Year REALITI-A Subanalysis
Chupp G, Heaney L, Pelaia G, Almonacid C, Maxwell A, Zhang L, Alfonso-Cristancho R, Howarth P, Brusselle G. Impact of Demographics on Mepolizumab Effectiveness in Severe Asthma: One-Year REALITI-A Subanalysis. The Journal Of Allergy And Clinical Immunology In Practice 2025, 13: 3286-3295. PMID: 40780384, DOI: 10.1016/j.jaip.2025.07.049.Peer-Reviewed Original ResearchConceptsClinically significant asthma exacerbationsBody mass indexPre-BD FEV1 (%Maintenance oral corticosteroidsSevere asthmaDemographic/clinical characteristicsObservational studyPost hoc subanalysisAsthma onsetACQ-5 scoresObservational study of adultsAge of asthma onsetOlder ageOlder age of onsetForced expiratory volumeReal-world studyMepolizumab treatmentOral corticosteroidsStudy of adultsSmoker subgroupsACQ-5Eosinophilic phenotypeMepolizumabAge-of-onsetFollow-upMilitary Inhalational Exposures Outside the Theater of Conflict and Chronic Respiratory Symptoms
Hosseini R, Garshick E, Slade M, Timmons A, Korpak A, Smith N, Nakayama K, Baird C, Ciminera P, Kheradmand F, Fan V, Hart J, Koutrakis P, Kuschner W, Ioachimescu O, Jerrett M, Montgrain P, Proctor S, Wendt C, Wongtrakool C, Wan E, Blanc P, Redlich C. Military Inhalational Exposures Outside the Theater of Conflict and Chronic Respiratory Symptoms. JAMA Network Open 2025, 8: e2522080. PMID: 40690216, PMCID: PMC12281241, DOI: 10.1001/jamanetworkopen.2025.22080.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsChronic respiratory symptomsCross-sectional studyUS veteransAssociated with adverse respiratory health outcomesAdverse respiratory health outcomesMilitary service durationVeterans Affairs sitesRespiratory health outcomesHealth of military personnelAssociated with wheezingRespiratory symptomsLong-term respiratory healthMulti-item questionnaireTheaters of conflictPrevalence of dyspneaUS DepartmentHealth outcomesExposure prevalenceChronic bronchitisVeterans StudyMain OutcomesAdjusted multivariate analysisExposure categoriesChronic lung diseaseOnsite visitsCyclic GMP-AMP synthase expression is enhanced in systemic sclerosis-associated interstitial lung disease and stimulates inflammatory myofibroblast activation
Yu S, Hu B, Sun Y, Peng X, Lee C, Woo S, McGovern J, Zielonka J, Saber T, Ghincea A, Gandhi S, Walia A, Pivarnik T, Ishikawa G, Shao S, Sun H, Gunes B, Kujawski S, Perez S, Odell W, Hinchcliff M, Varga J, Feghali-Bostwick C, Sauler M, Gomez J, Ryu C, Herzog E. Cyclic GMP-AMP synthase expression is enhanced in systemic sclerosis-associated interstitial lung disease and stimulates inflammatory myofibroblast activation. European Respiratory Journal 2025, 66: 2401564. PMID: 40374521, PMCID: PMC12332468, DOI: 10.1183/13993003.01564-2024.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPrecision cut lung slicesSSc-ILD lung tissuesType 1 interferonSSc-ILDProduction of cytokinesBronchoalveolar lavageHuman precision cut lung slicesLung tissueLung fibroblastsLungs of patientsInterstitial lung diseasePulmonary fibrosis modelBleomycin mouse modelIsolated lung fibroblastsCultured fibroblastsPerturbs innate immunityFibrotic stimuliSingle cell RNA sequencing datasetsSystemic sclerosisHuman lung fibroblastsLung diseaseMouse modelCyclic GMP-AMP synthaseFibrosis modelTherapeutic approachesHypersensitivity pneumonitis associated with home mold exposure: A retrospective cohort analysis
Adams T, Redlich C, Glazer C, Gulati M. Hypersensitivity pneumonitis associated with home mold exposure: A retrospective cohort analysis. PLOS ONE 2025, 20: e0323093. PMID: 40338891, PMCID: PMC12061107, DOI: 10.1371/journal.pone.0323093.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsDiagnosis of HPHP patientsRetrospective cohort of patientsMold exposureTransplant free survivalCohort of patientsRetrospective cohort analysisMedical chart reviewDevelopment of HPHypersensitivity pneumonitis patientsHome moldFibrotic HPFree survivalAntigen exposureChart reviewConfident diagnosisRetrospective cohortPneumonic patientsInvasive proceduresHypersensitivity pneumonitisCohort analysisCulprit antigenPatientsImprove outcomesCohortThe Potential Role of GPR87 in the Development of Pulmonary Fibrosis
Khoury J, Ahangari F, Justet A, Adams T, Manning E, Mcdonough J, Anderson S, Nekola F, Beermann M, Bauer Y, Gomez J, Kaminski N. The Potential Role of GPR87 in the Development of Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a7110-a7110. DOI: 10.1164/ajrccm.2025.211.abstracts.a7110.Peer-Reviewed Original ResearchSex-Specific Immune Transcriptional Programming by Pseudomonas in Cystic Fibrosis
Knight C, Yin H, Kockar Kizilirmak T, Adams T, Sauler M, Gomez J, Britto-Leon C. Sex-Specific Immune Transcriptional Programming by Pseudomonas in Cystic Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a1109-a1109. DOI: 10.1164/ajrccm.2025.211.abstracts.a1109.Peer-Reviewed Original ResearchHigh Exacerbators in Cystic Fibrosis Have Sex-Specific Neutrophil Transcriptomes
Knight C, Yin H, Kockar Kizilirmak T, Adams T, Sauler M, Gomez J, Britto-Leon C. High Exacerbators in Cystic Fibrosis Have Sex-Specific Neutrophil Transcriptomes. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a5557-a5557. DOI: 10.1164/ajrccm.2025.211.abstracts.a5557.Peer-Reviewed Original ResearchHigher Acute Exposure to Air Pollution Is Associated With Respiratory Hospitalizations in Idiopathic Pulmonary Fibrosis: Data From the IPF-PRO Registry
Sack C, Wojdyla D, Macmurdo M, Gassett A, Redlich C, Raghu G, Kaufman J, Olson A, Neely M, Snyder L, Gulati M, on behalf of the IPF-PRO Registry investigators. Higher Acute Exposure to Air Pollution Is Associated With Respiratory Hospitalizations in Idiopathic Pulmonary Fibrosis: Data From the IPF-PRO Registry. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a3245-a3245. DOI: 10.1164/ajrccm.2025.211.abstracts.a3245.Peer-Reviewed Original ResearchCivilian Occupational Exposures and Current Respiratory Symptoms in Veterans Previously Deployed to Southwest Asia and Afghanistan
Mohazzab-Hosseinian S, Redlich C, Timmons A, Korpak A, Smith N, Nakayama K, Baird C, Ciminera P, Kheradmand F, Fan V, Hart J, Koutrakis P, Kuschner W, Ioachimescu O, Jerrett M, Montgrain P, Proctor S, Wendt C, Wongtrakool C, Wan E, Garshick E, Blanc P. Civilian Occupational Exposures and Current Respiratory Symptoms in Veterans Previously Deployed to Southwest Asia and Afghanistan. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a4259-a4259. DOI: 10.1164/ajrccm.2025.211.abstracts.a4259.Peer-Reviewed Original ResearchConceptsBlast Exposure and Associations With Respiratory Symptoms Among Deployed Military Veterans to Southwest Asia and Afghanistan
Henkle B, Gravely A, Redlich C, Timmons A, Korpak A, Smith N, Nakayama K, Baird C, Ciminera P, Kheradmand F, Fan V, Hart J, Koutrakis P, Kuschner W, Ioachimescu O, Jerrett M, Montgrain P, Proctor S, Wongtrakool C, Wan E, Garshick E, Blanc P, Wendt C. Blast Exposure and Associations With Respiratory Symptoms Among Deployed Military Veterans to Southwest Asia and Afghanistan. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a4261-a4261. DOI: 10.1164/ajrccm.2025.211.abstracts.a4261.Peer-Reviewed Original ResearchConceptsThe Role of Non-coding RNAs in Asthma T2-high and T2-low Endotypes
Zielonka J, Kay S, Chupp G, Gomez J. The Role of Non-coding RNAs in Asthma T2-high and T2-low Endotypes. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a3430-a3430. DOI: 10.1164/ajrccm.2025.211.abstracts.a3430.Peer-Reviewed Original ResearchAsthma Exacerbations: Integrative Analysis of Mirna Activity in Using Single-cell Transcriptomics
Hadikhani P, Yan X, Chupp G, Liu Q, Ban G, Piparia S, Mcgeachie M, Sharma R, Weiss S, Kho A, Tantisira K. Asthma Exacerbations: Integrative Analysis of Mirna Activity in Using Single-cell Transcriptomics. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a7773-a7773. DOI: 10.1164/ajrccm.2025.211.abstracts.a7773.Peer-Reviewed Original ResearchTwice-yearly Depemokimab Reduces Exacerbations and Improves Quality of Life in Patients With Uncontrolled Asthma Symptoms at Baseline: Subgroup Analyses of the Phase III SWIFT-1/2 Studies
Pavord I, Chupp G, Jackson D, Muccino D, Forth R, Kwiatek J, Vichiendilokkul A, Jackson D. Twice-yearly Depemokimab Reduces Exacerbations and Improves Quality of Life in Patients With Uncontrolled Asthma Symptoms at Baseline: Subgroup Analyses of the Phase III SWIFT-1/2 Studies. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a5234-a5234. DOI: 10.1164/ajrccm.2025.211.abstracts.a5234.Peer-Reviewed Original ResearchAltmetricConceptsMicroRNA-223 Targets the FOXO1 Transcription Factor and Inflammatory Genes Involved in Asthma in Bronchial Epithelial Cells
Korde A, Ramirez M, Dubovik V, Zheng S, Yan X, Gomez J. MicroRNA-223 Targets the FOXO1 Transcription Factor and Inflammatory Genes Involved in Asthma in Bronchial Epithelial Cells. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a2482-a2482. DOI: 10.1164/ajrccm.2025.211.abstracts.a2482.Peer-Reviewed Original ResearchCharacterization of Gene Networks Associated With ALOX15 Expression in Type 2-High Asthma
Shuguli M, Dubovik V, Ramirez M, Korde A, Gomez J. Characterization of Gene Networks Associated With ALOX15 Expression in Type 2-High Asthma. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a3492-a3492. DOI: 10.1164/ajrccm.2025.211.abstracts.a3492.Peer-Reviewed Original ResearchImpact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease.
Johannson K, Adegunsoye A, Behr J, Cottin V, Glanville A, Glassberg M, Goobie G, Jenkins R, Kim J, Lee C, Redlich C, Richeldi L, Salisbury M, Tetley T, Corte T. Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease. American Journal Of Respiratory And Critical Care Medicine 2025, 211: 560-568. PMID: 39745380, DOI: 10.1164/rccm.202409-1730pp.Peer-Reviewed Original ResearchCitationsAltmetricImpact of atopic status, prior omalizumab use and baseline blood eosinophil count alone and in combination with total serum IgE on maintenance OCS reduction outcomes in patients with severe asthma treated with mepolizumab in the REALITI-A study
Liu M, Chaudhuri R, Chupp G, Heaney L, Lee J, Pilette C, Brusselle G, Alfonso-Cristancho R, Zhang L, Howarth P, Kumar A. Impact of atopic status, prior omalizumab use and baseline blood eosinophil count alone and in combination with total serum IgE on maintenance OCS reduction outcomes in patients with severe asthma treated with mepolizumab in the REALITI-A study. Revue Française D'Allergologie Et D'Immunologie Clinique 2025, 65: 104319. DOI: 10.1016/j.reval.2025.104319.Peer-Reviewed Original ResearchConceptsBaseline blood eosinophil countBlood eosinophil countProportion of patientsAtopic statusDaily doseDose reductionOmalizumab useEosinophil countSevere asthmaDaily dose reductionSerum total IgEDaily dose dataReal-world treatmentReal-world studyPost Hoc AnalysisAdverse event riskSingle-armIL-5Total IgEDose dataOmalizumabClinical trialsMepolizumabPatientsEvent riskProspective REALITI-A Study 2-Year Real-World Benefits of Mepolizumab in Severe Asthma
Caruso C, Canonica G, Patel M, Smith A, Liu M, Alfonso-Cristancho R, Price R, Jakes R, Demetriou L, Valero A, Köhler T, Pilette C, Chupp G, Brusselle G, Howarth P. Prospective REALITI-A Study 2-Year Real-World Benefits of Mepolizumab in Severe Asthma. CHEST Pulmonary 2025, 3: 100107. DOI: 10.1016/j.chpulm.2024.100107.Peer-Reviewed Original ResearchCitationsConceptsFollow-up periodMepolizumab treatmentAdverse eventsSevere asthmaRate of clinically significant asthma exacerbationsFollow-upMonoclonal antibodies targeting interleukin-5Clinically significant asthma exacerbationsMaintenance oral corticosteroidsAssociated with sustained reductionsProportion of patientsACQ-5 scoresAsthma Control QuestionnaireForced expiratory volumeOral corticosteroidsWell-toleratedACQ-5Clinical benefitMepolizumabProspective studyWeeks 0Asthma exacerbationsInterleukin-5Expiratory volumeSustained reductionLong-Term Air Pollution Exposure and Severity of Idiopathic Pulmonary Fibrosis: Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry.
Sack C, Wojdyla D, MacMurdo M, Gassett A, Kaufman J, Raghu G, Redlich C, Li P, Olson A, Leonard T, Todd J, Neely M, Snyder L, Gulati M, Baker A, Beegle S, Belperio J, Condos R, Cordova F, Southern B, Dilling D, Fitzgerald J, Flaherty K, Gibson K, Gulati M, Guntupalli K, Gupta N, Case A, Hotchkin D, Huie T, Kaner R, Kim H, Lancaster L, Lasky J, Lee D, Liesching T, Lipchik R, Lobo J, Luckhardt T, Mageto Y, Kokoszynska M, Morrison L, Namen A, Oldham J, Paul T, Zhang D, Porteous M, Raj R, Ramaswamy M, Russell T, Sachs P, Safdar Z, Shafazand S, Siddiqi A, Fowler R, Strek M, Rivas-Perez H, Tabak J, Walia R, Whelan T. Long-Term Air Pollution Exposure and Severity of Idiopathic Pulmonary Fibrosis: Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Annals Of The American Thoracic Society 2025, 22: 378-386. PMID: 39531618, DOI: 10.1513/annalsats.202404-382oc.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAssociated with worse qualityExposure to air pollutionGene-environment interactionsQuality of lifePollution exposureEffects of long-term exposure to air pollutionLong-term exposure to PM2.5 anLong-term exposure to air pollutionWorse qualityParticipant's residential addressQuality of life measuresNon-Hispanic whitesExposure to PM2.5Multi-pollutant modelsYears of follow-upCox proportional hazards modelsLower FVC %Residential addressesProportional hazards modelIPF-PRO RegistryMultivariate regression modelEffect modificationEuroQol scoresLife measuresEnrollment dateSilicosis: A Chronic Work-related Lung Disease
Fazio J, Heinzerling A, Gandhi S, Redlich C, Cummings K. Silicosis: A Chronic Work-related Lung Disease. ATS Scholar 2025, 6: 113-116. PMID: 39964259, PMCID: PMC11984649, DOI: 10.34197/ats-scholar.2024-0118pe.Peer-Reviewed Original ResearchAltmetric